SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

December 13, 2012 07:00 ET

Implant Sciences Adds Director to Oversee Worldwide Service Organization for Growing Installed Base of Quantum Sniffers

WILMINGTON, MA--(Marketwire - Dec 13, 2012) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has hired industry veteran Mark Edgeworth as Director of Field Service and Technical Training.

Mr. Edgeworth will oversee the continued development of Implant Sciences' global service and training organization, which includes providing training to end-users and distributors of the Company's explosives and drugs trace detectors. Mr. Edgeworth will also expand Implant Sciences' technical training programs for distributors. Implant Sciences offers global service for its Quantum Sniffers™ which, with very few disposable parts and high reliability rates, require minimal service compared to competing products.

Mr. Edgeworth has extensive training and customer support experience with security industry leaders, including GE Infrastructure Security. He was also formerly the Applications Training Manager for GE Homeland Protection (formerly GE Ion Track and Invision Technologies) and the Field Training Manager at GE Ion Track (formerly Ion Track Instruments).

As Applications Training Manager and Field Training Manager, Mr. Edgeworth was directly responsible for worldwide installation services and customer training for explosive trace (ETD) and explosive detection (EDS) equipment. Mr. Edgeworth brings a wealth of deployment and servicing experience to Implant Sciences. His expertise, from having worked with a variety of domestic and foreign government agencies, including the TSA, Department of Defense, and others will be a major asset to Implant Sciences' growing worldwide service and training organization.

"Mark is an industry veteran who has comprehensive experience in both trace detection technology and field service leadership. His skills will translate into immediate results in building and enhancing our service and training organization. As the number of installed Quantum Sniffers grows, it becomes more important to have a robust organization for training new users and distributors," stated Brenda Baron, Implant Sciences' Vice President of Manufacturing and Technical Services.

"We experience a high rate of repeat purchases from current customers. This is based, in part, on the high level of customer training and service we provide," added Glenn D. Bolduc, Implant Sciences' President and CEO. "We welcome Mark as the latest addition to our cadre of explosives industry professionals. His track record of having trained TSA personnel is particularly timely for us as we continue to work toward having our QS-B220 desktop explosives and drugs trace detector added to the TSA's 'Air Cargo Screening Technology List - For Passenger Aircraft.'"

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact